Literature DB >> 26649663

Data confusion.

Sunil Bhandari1, Philip A Kalra2, Daniel W Coyne3.   

Abstract

Year:  2015        PMID： 26649663     DOI： 10.1038/ki.2015.303

Source DB:  PubMed          Journal:  Kidney Int        ISSN： 0085-2538            Impact factor:   10.612


× No keyword cloud information.
  2 in total

1.  Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†.

Authors:  Piotr Ponikowski; Dirk J van Veldhuisen; Josep Comin-Colet; Georg Ertl; Michel Komajda; Viacheslav Mareev; Theresa McDonagh; Alexander Parkhomenko; Luigi Tavazzi; Victoria Levesque; Claudio Mori; Bernard Roubert; Gerasimos Filippatos; Frank Ruschitzka; Stefan D Anker
Journal:  Eur Heart J       Date:  2014-08-31       Impact factor: 29.983

2.  FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia.

Authors:  Iain C Macdougall; Andreas H Bock; Fernando Carrera; Kai-Uwe Eckardt; Carlo Gaillard; David Van Wyck; Bernard Roubert; Jacqueline G Nolen; Simon D Roger
Journal:  Nephrol Dial Transplant       Date:  2014-06-02       Impact factor: 5.992
  2 in total
  3 in total

Review 1.  Intravenous iron therapy in patients with chronic kidney disease: recent evidence and future directions.

Authors:  Iain C Macdougall
Journal:  Clin Kidney J       Date:  2017-11-28

2.  Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial.

Authors:  Sunil Bhandari; Philip A Kalra; Mario Berkowitz; Diogo Belo; Lars L Thomsen; Myles Wolf
Journal:  Nephrol Dial Transplant       Date:  2021-01-01       Impact factor: 5.992

Review 3.  Iron Sucrose: A Wealth of Experience in Treating Iron Deficiency.

Authors:  Iain C Macdougall; Josep Comin-Colet; Christian Breymann; Donat R Spahn; Ioannis E Koutroubakis
Journal:  Adv Ther       Date:  2020-04-15       Impact factor: 3.845
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.